Actinogen Medical Limited Overview
Actinogen Medical is a Sydney-based, ASX-listed, clinical-stage biotechnology company with a single platform asset, Xanamem (emestedastat), a brain-penetrant, once-daily oral inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which regenerates active cortisol inside brain cells. The company's thesis is that chronically elevated brain cortisol damages neurons and contributes to cognitive decline and mood disorders, and that lowering it intracellularly can slow Alzheimer's disease (AD) progression and treat depressive symptoms. Its pivotal Phase 2b/3 XanaMIA trial (247 participants with biomarker-confirmed progressive mild-to-moderate AD, 10 mg vs placebo over 36 weeks) completed its last patient visit on 22 September 2026, with topline results guided for November 2026. Actinogen positions Xanamem as a convenient oral alternative or complement to infusion-based anti-amyloid antibodies, avoiding the MRI-monitoring burden associated with ARIA. Pre-revenue, it funds itself through equity raisings and Australia's refundable R&D Tax Incentive.
What the company does
Actinogen is a drug developer, not a commercial-stage pharmaceutical company. Its entire enterprise value rests on Xanamem. The company in-licensed/acquired the molecule (originally discovered at the University of Edinburgh, coded UE2343) through its acquisition of Corticrine Limited in the mid-2010s, then reshaped itself from an earlier natural-products (actinomycete-derived antibiotic) discovery business into a neuroscience company.
The company's own description (repeated in ASX announcements and the FY2025/FY2026 annual report boilerplate) is that it is developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol, targeting the substantial unmet need in cognitive dysfunction and behavioural abnormalities. In 2026 communications it describes itself as being in the late clinical stages of developing Xanamem for Alzheimer's disease and depression.
Business model
Development model: Virtual/outsourced. Clinical trials are run through contract research organisations (CROs) and investigator sites in Australia and the United States; drug substance and tablet manufacture are outsourced (commercial-grade 10 mg tablets produced at Catalent's US facility; a 15 kg drug-substance batch has been manufactured).
Monetisation pathway (stated): If XanaMIA is positive, management intends to pursue regulatory engagement on accelerated pathways (including with the US FDA), run a second, larger multinational pivotal trial (planned for 2027), and, per sponsored research commentary, seek a potentially transformative licensing/partnering deal. A Chief Commercial Officer was appointed in FY2025 and market research is under way.
Revenue model mix: Product 0%, service 0%, subscription 0%, licensing 0%. Reported "revenue and other income" is overwhelmingly the refundable Australian R&D Tax Incentive (e.g. A$12.67m of A$13.17m total income in FY2026), plus interest.
Value-chain position
Actinogen sits at the discovery/clinical-development end of the pharmaceutical value chain, owning IP and clinical data. It has no sales force, distribution or manufacturing plants. Value capture would come via (a) out-licensing to a large pharma with commercial infrastructure in neurology, (b) a co-development deal, or (c) acquisition.
Customer types and end-markets (prospective)
Ultimate patients: People aged 50+ with mild-to-moderate AD and biomarker-confirmed progressive disease (elevated plasma pTau181); patients with major depressive disorder (MDD) with cognitive impairment; historically fragile X syndrome was explored.
Prescribers: Neurologists, geriatricians, psychiatrists, and potentially primary care (an oral pill without MRI monitoring is a key differentiator versus infusion antibodies).
Payers: US Medicare/commercial payers, European national health systems, Australian PBS.
Near-term "customers": Potential pharma licensees.
Independent characterisation
Actinogen is a high-risk, binary, single-asset micro/small-cap biotech whose risk profile has been partially reduced by (i) three positive independent Data Monitoring Committee (DMC) reviews, including a January 2026 interim efficacy non-futility review, (ii) over-enrolment of XanaMIA (247 vs original target), (iii) regulatory alignment with FDA (September 2025 Type C meeting) and EMA (scientific advice, May 2026), and (iv) a funded runway beyond the readout into mid-2027. However, the mechanism has historical failures: the company's own XanADu Phase 2 trial (2019) missed its primary endpoints, and an earlier 11β-HSD1 inhibitor from a large pharma did not show efficacy in AD. The current trial's enrichment strategy (pTau181-elevated patients) is based on post-hoc analysis of XanADu, which is a recognised source of risk.
Strategy
Stated strategy (themes from FY2025–FY2026 reporting)
-
Deliver XanaMIA — complete the pivotal Phase 2b/3 trial and report topline efficacy and safety in November 2026.
-
Regulatory acceleration — use FDA (Sept 2025) and EMA (May 2026) alignment on a streamlined pathway; explore accelerated-approval options if results are positive.
-
Second pivotal trial (2027) — larger, multinational, two-arm 10 mg vs placebo design.
-
Commercial readiness — CCO appointment, market research, commercial-grade manufacturing at Catalent, 15 kg API scale.
-
Long-term data via OLE — up to 24 months of active treatment data compared with historical controls.
-
Depression optionality — leverage XanaCIDD's published antidepressant signal; further MDD trials contingent on independent funding/partnering.
-
Capital discipline — combine equity, R&D tax incentive and rebate-backed lending to reach the readout without distress.
-
Partnering — sponsored research indicates management aims for a licensing deal post-readout.
Initiatives in the last 24 months
| Date | Initiative |
|---|---|
| Sep 2024 | A$11.1m placement and SPP to fund XanaMIA expansion |
| 2024–2025 | A$13.8m non-dilutive R&D tax incentive funding facility |
| 2,025 | INN emestedastat obtained; FDA Type C (MDD) |
| 2,025 | Chief Commercial Officer appointed; commercial market research |
| Sep 2025 | FDA Type C (AD) — pathway agreed |
| Feb 2026 | ~A$16.8m capital raising |
| Mar 2026 | XanaMIA-OLE launched |
| May 2026 | EMA scientific advice received |
| 2,026 | Endpoints Capital loan (A$4.32m) against FY2026 rebate |
| 2,026 | Forrest Capital underwriting of unlisted options (~A$4.77m) |
ESG commitments and cost-programme targets: not publicly disclosed.
Medium-term targets / guidance
No financial targets (company is pre-revenue). Operational guidance: XanaMIA topline November 2026; second pivotal trial 2027; cash runway beyond mid-2027.
Products & Services
Actinogen has no marketed products. The portfolio is a single molecule pursued across several indications.
Xanamem® (emestedastat) — core asset
| Attribute | Detail |
|---|---|
| Modality | Small molecule, oral, once daily |
| Mechanism | Selective inhibitor of 11β-HSD1, the enzyme that converts inactive cortisone into active cortisol within cells; designed to cross the blood-brain barrier and lower intracellular brain cortisol |
| Dose in pivotal programme | 10 mg once daily |
| Formulation | Commercial-grade 10 mg tablets manufactured at Catalent (USA) |
| Origin | University of Edinburgh discovery (code UE2343), acquired via Corticrine |
| INN | Emestedastat (WHO, 2025) |
| Trademark | Xanamem® |
| Differentiation claims | Oral; no requirement for serial MRI safety monitoring (unlike anti-amyloid antibodies); mechanism independent of amyloid; potential for combination use |
| Pricing | Not disclosed (no approved product) |
Indication programmes
| Programme / trial | Indication | Phase | Design | Status (Oct 2026) |
|---|---|---|---|---|
| XanaMIA | Mild-to-moderate AD with progressive disease confirmed by elevated plasma pTau181 | Phase 2b/3 (pivotal) | Randomised, double-blind, placebo-controlled; 10 mg vs placebo for 36 weeks; 247 participants; Australia and US sites | Last patient visit 22 Sep 2026; topline November 2026; three positive DMC reviews |
| XanaMIA-OLE | Same population (current and former XanaMIA participants) | Open-label extension | Active 10 mg for up to 24 months; rolling data comparison vs historical controls and randomised phase | Began March 2026; ~89% of eligible participants transitioned; 108 on treatment (Aug 2026) |
| Second pivotal AD trial | AD | Phase 3 (planned) | Two-arm, 10 mg vs placebo, larger and multinational, agreed with FDA | Planned for 2027 |
| XanaCIDD | MDD with cognitive impairment (adjunctive) | Phase 2a (completed) | Randomised placebo-controlled | Antidepressant activity on MADRS and patient-reported scales; published in British Journal of Psychiatry (2026); further MDD trials pending independent funding/partnering |
| XanADu | Mild AD | Phase 2 (completed 2019) | 20 mg/day, 12 weeks | Primary endpoints missed; post-hoc pTau181 subgroup signal underpins XanaMIA |
| XanaHES | Healthy elderly | Phase 1b (completed) | Cognitive effects at 10/20 mg | Signals on attention/working memory |
| XanaFX (historical) | Fragile X syndrome | Planned Phase 2 (historical) | — | Not an active priority in 2025–2026 disclosures |
Financial Narrative
Context: As a pre-revenue biotech, conventional margin, EBITDA-multiple and return metrics are mathematically negative or not meaningful. The relevant analytics are cash burn, runway, R&D intensity and funding mix.
Income statement
Notes and sources: FY2022 loss before tax of A$9,497,370 and FY2022 R&D rebate of A$3,640,082 from the FY2022 Appendix 4E (ASX, 25 Aug 2022). FY2025 net loss of A$14,732,263 and FY2024 net loss of A$13,044,282 from the FY2025 Annual Report. FY2026 net loss of A$15,379,848, total income A$13.17m, R&D rebate A$12.67m and R&D expense A$19.03m from the FY2026 results release (27 Aug 2026). FY2023 figures and FY2023–FY2025 income/SG&A splits from Stock Analysis aggregation of filings (not reconciled line-by-line). FY2026 SG&A not separately captured in sources reviewed; the residual of all non-R&D expenses (G&A, share-based payments, finance costs including the Endpoints Capital loan) is derived at approximately A$9.5m.
Margins and growth: Gross, operating, EBITDA and net margins are not meaningful (no sales). Revenue CAGR is not meaningful. The net loss CAGR FY2022–FY2026 is approximately 12.8% per year, reflecting a step-up in clinical activity rather than cost indiscipline.
Balance sheet: notes and sources
Sources: FY2025 cash A$16,504,230 (FY2025 Annual Report); FY2026 cash A$16,734,937 and FY2026 rebate accrual A$10,817,407 (FY2026 results release); Endpoints Capital loan A$4.32m (FY2026 results coverage). Interim reference points: cash A$11.47m at 31 Dec 2023 (Google Finance), A$10.41m at 30 Sep 2025 (Sep-2025 Appendix 4C), A$6.5m at 31 Dec 2025 with A$29.7m pro forma after the February 2026 raise and R&D rebate (H1 FY2026 results). Net debt: net cash position in all years (FY2026 net cash approx. A$12.4m before the rebate receivable).
Cash flow: notes and sources
Sources: Stock Analysis aggregation (FCF ≈ operating cash flow given negligible capex). FY2026 operating cash flow not captured; Q1 FY2026 operating outflow was A$6.1m (Sep-2025 4C). Year-to-year FCF volatility is largely timing of R&D rebate receipts (e.g. the FY2024 rebate of A$9.0m was received in October 2024, i.e. in FY2025, flattering FY2025 FCF).
Commentary
The five-year pattern is a steadily rising loss (A$9.5m to A$15.4m) driven by R&D (A$8.2m to A$19.0m) as XanaMIA expanded into a pivotal trial and XanaCIDD ran in parallel. The Australian R&D Tax Incentive is a material, structural offset: the FY2026 rebate of A$12.67m covered roughly two-thirds of R&D expense, which is why the net loss rose only modestly despite a 55% jump in R&D. The inflection points are FY2024 (XanaMIA scale-up, R&D +75%) and FY2026 (full enrolment, OLE start, manufacturing). Funding has come from repeated small-to-mid-size equity raisings (rights issues 2020, 2023, 2024; placement + SPP Sep 2024; ~A$16.8m Feb 2026), non-dilutive rebate-backed facilities (A$13.8m facility; Endpoints Capital loan) and option exercises (an underwriting by Forrest Capital of remaining unlisted options worth ~A$4.77m was announced). Share count growth has been substantial (~2.3bn shares at Dec 2023 to ~3.7bn implied in 2026), a dilution cost that should be weighed against the progress achieved.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products |
|---|---|---|
Single segment: Pharmaceutical R&D | Clinical development of Xanamem (emestedastat) across AD and MDD; manufacturing scale-up; regulatory and commercial readiness | Xanamem 10 mg oral tablet (investigational) |
Results by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment total income (AUD Mn) | 9.93 | 5.49 | 13.17 |
Segment net loss after tax (AUD Mn) | -13.04 | -14.73 | -15.38 |
Share of group income (%) | 100 | 100 | 100 |
Income Statement
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from contracts with customers (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Total revenue and other income (AUD Mn) | 3.64 | 4.89 | 9.93 | 5.49 | 13.17 |
of which R&D tax rebate (AUD Mn) | 3.64 | — | — | — | 12.67 |
R&D expense (AUD Mn) | 8.21 | 8.90 | 15.54 | 12.30 | 19.03 |
SG&A expense (AUD Mn) | 3.27 | 5.05 | 5.93 | 6.46 | — |
Net loss after tax (AUD Mn) | -9.50 | -10.75 | -13.04 | -14.73 | -15.38 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD Mn) | — | — | — | 16.50 | 16.73 |
R&D tax rebate receivable/accrued (AUD Mn) | — | — | — | — | 10.82 |
Borrowings – R&D tax-backed loan (AUD Mn) | 0 | 0 | 0 | — | 4.32 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Free cash flow (AUD Mn) | -9.52 | -8.73 | -16.96 | -7.59 | — |
Capex (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Financial Analysis
| Ratio | Assessment |
|---|---|
ROE / ROA / ROIC | Deeply negative; not meaningful for a pre-revenue developer (Google Finance cited ROA of roughly -103% at Dec 2023) |
Debt/equity | Low; only R&D-tax-backed lending |
Net debt/EBITDA, interest coverage | Not meaningful (negative EBITDA, net cash) |
Runway | Company guides funding beyond XanaMIA results to mid-2027 (FY2026 results; CFO commentary July 2026) |
Results by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia income (AUD Mn) | 9.93 | 5.49 | 13.17 |
Americas income (AUD Mn) | 0 | 0 | 0 |
EMEA income (AUD Mn) | 0 | 0 | 0 |
Market Valuation and Share Price
| Metric | FY2025 | FY2026 |
|---|---|---|
Market cap at 30 June (AUD Mn) | 73.07 | 115.23 |
Share price at 30 June (AUD) | 0.02 | 0.03 |
Value by Reference Point
| Reference point | Value |
|---|---|
Share price late Jan 2026 | ~A$0.050 (Investing.com) |
Share price 26 Feb 2026 (H1 release) | A$0.041–0.046 |
Share price late Jul / early Aug 2026 | A$0.042–0.043 |
Recent observation (Sep/Oct 2026, aggregators) | ~A$0.037; market cap ~A$128–133m |
52-week range | A$0.023 – A$0.072 |
1-year relative performance | Outperformed the ASX All Ordinaries by ~54% (Stockopedia, mid-2026) |
Analyst Conclusions
Management guidance
-
XanaMIA topline 36-week efficacy and safety results: November 2026.
-
Ongoing rolling XanaMIA-OLE data.
-
Second, larger multinational pivotal AD trial planned for 2027.
-
Exploration of accelerated approval with FDA if results are positive.
-
Cash runway beyond mid-2027 (before any new raise).
-
No revenue or earnings guidance.
Consensus
Formal consensus revenue/EPS expectations are not meaningful; coverage is thin (~2 analysts per aggregators), with a cited target price of A$0.08.
Bull case
-
De-risked readout: The January 2026 interim analysis cleared an efficacy non-futility bar and all three DMC safety reviews were clean, raising the probability of a positive topline above historical AD base rates.
-
Commercial differentiation: An oral, once-daily pill without MRI monitoring would address the main practical barriers limiting uptake of anti-amyloid antibodies, in a market referenced at ~US$20bn.
-
Funded optionality: A$16.7m cash plus A$10.8m rebate receivable fund the company beyond readout, strengthening its negotiating position for a licensing deal and preserving an MDD option backed by peer-reviewed data.
Bear case
-
Mechanism history: XanADu failed its primary endpoints in 2019; XanaMIA's enrichment rests on a post-hoc subgroup, and oral AD agents from much larger sponsors have repeatedly failed in Phase 3.
-
Capital intensity ahead: Even a positive result requires a larger multinational pivotal trial in 2027; without a partner, this implies heavy dilution of a share base already ~3.7bn.
-
Single-asset fragility: With no other pipeline asset, a negative or ambiguous result would leave little residual value beyond cash.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst |
|---|---|
| Oct 2026 | Annual Report lodgement (~14 Oct); September-quarter 4C |
| Nov 2026 | XanaMIA topline results (primary and key secondary endpoints, pTau-defined effect size, safety) |
| Nov 2026 | AGM |
| Q2 FY2027 | Receipt of ~A$10.8m FY2026 R&D rebate; repayment of Endpoints loan |
| Late 2026–2027 | FDA/EMA meetings on accelerated pathways; partnering discussions |
| 2,027 | Second pivotal trial initiation and its funding structure |
| Ongoing | XanaMIA-OLE long-term data; scientific presentations (e.g. CTAD conference) |
Analyst verdict
Actinogen Medical is approaching the defining moment of its 27-year corporate life. After pivoting from antibiotic discovery to neuroscience a decade ago and absorbing a painful Phase 2 failure in 2019, the company has rebuilt its Xanamem thesis around biomarker-selected patients, regulatory alignment and disciplined, rebate-supported funding. The operational record of the past two years is genuinely strong for a company of its size: XanaMIA over-enrolled to 247 participants, passed an interim efficacy futility test and three safety reviews, began a well-subscribed open-label extension, secured FDA and EMA input, and completed commercial-grade manufacturing — all with an annual net loss held to about A$15m thanks to Australia's R&D Tax Incentive.
Yet the investment case remains fundamentally binary. Interim non-futility is a low bar compared with demonstrating a statistically and clinically meaningful benefit over 36 weeks, and the scientific premise depends on a subgroup finding from a failed trial. The broader field has punished oral, non-amyloid hypotheses repeatedly, including from far better-resourced sponsors. At a market capitalisation of roughly A$130–160m, the market appears to be pricing a meaningful but far from certain probability of success, a reasonable stance given the asymmetric outcomes: a clearly positive readout would likely unlock partnering interest and a material rerating, while a miss would likely compress value towards cash.
For institutional readers, the prudent framing is event-driven: position sizing should reflect a high-variance outcome in November 2026, with key monitorables being the magnitude and consistency of effect across cognitive and functional endpoints, the safety profile, and management's financing or partnering plan for the 2027 pivotal trial. Governance, insider alignment (CEO ~5.5%) and disclosure quality are adequate for a micro-cap biotech; the principal unresolved issue is dilution. Overall verdict: speculative, catalyst-driven, high-risk/high-reward; neutral until the topline data are known.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background |
|---|---|---|
Dr Steven Gourlay | CEO and Managing Director | CEO since 14 March 2021; physician with prior biotech/medtech board roles (e.g. Elastagen, Applied Physiology, Endoluminal Sciences); holds ~203m shares (~5.5%) per June 2026 notices |
Dr Dana Hilt | Chief Medical Officer | Leads clinical programme; US neurology drug-development veteran (details per company website) |
Will Souter | Chief Financial Officer | — |
Tamara Miller | SVP Product Development | Per aggregator listing |
Fujun Li | Head of Manufacturing | Per aggregator listing |
Peter Webse | Company Secretary | Per aggregator listing |
Michael Roberts | Investor Relations | Named IR contact on ASX releases |
Board of Directors
| Name | Role | Notes |
|---|---|---|
Dr Geoffrey Brooke | Non-Executive Chair | Healthcare venture capitalist (founder of GBS Venture Partners; MedVest); also chairs Cynata Therapeutics, director of Acrux and Saluda Medical; ~39.2m shares (~1.05%) |
Dr Steven Gourlay | Managing Director | Executive |
Malcolm McComas | Non-Executive Director | 9.8m direct shares (June 2026) |
Dr George Morstyn | Non-Executive Director | Former senior R&D executive (Amgen/CSL background); ~15.2m direct shares |
Dr Nicki Vasquez | Non-Executive Director | ~10.9m direct shares |
Competitive Landscape
Key Competitors
| Competitor | Asset / approach | Status (as generally reported) | Relevance to Actinogen |
|---|---|---|---|
Eisai / Biogen | Leqembi (lecanemab), anti-amyloid IV/subcutaneous antibody | Approved (US, EU, others) | Standard of care benchmark; MRI-monitoring burden is Xanamem's key contrast point |
Eli Lilly | Kisunla (donanemab), anti-amyloid antibody | Approved | Same as above |
Novo Nordisk | Oral semaglutide in early AD (evoke/evoke+) | Phase 3 reported as not meeting primary endpoints (late 2025) | Showed the difficulty of non-amyloid oral approaches |
Anavex Life Sciences | Blarcamesine (oral sigma-1 agonist) | EU regulatory setbacks reported | Oral competitor; cautionary precedent |
Alzheon | Valiltramiprosate (oral, APOE4/4) | Phase 3 missed primary endpoint (reported 2025) | Oral competitor |
Cassava Sciences | Simufilam | Discontinued after Phase 3 failures | Cautionary precedent |
Athira Pharma | Fosgonimeton | Phase 2/3 failure | Cautionary precedent |
Annovis Bio | Buntanetap (oral) | Phase 3 ongoing | Oral competitor |
Cognition Therapeutics | Zervimesine (CT1812, oral) | Phase 2 | Oral competitor |
AC Immune, Prothena, others | Anti-tau/anti-amyloid antibodies and vaccines | Clinical | Disease-modifying pipeline |
Sparrow Pharmaceuticals | Clofutriben (11β-HSD1 inhibitor) | Clinical in endocrine/inflammatory indications | Mechanistic peer, not in AD |
Generic antidepressants / J&J (Spravato) / others | MDD therapies | Approved | Competitive context for depression programme |
Peer Comparison FY2026
| Dimension | Actinogen | Anti-amyloid antibodies (Eisai/Lilly) | Other oral small molecules |
|---|---|---|---|
Route | Oral once daily | IV/SC infusion or injection | Oral |
Monitoring | No MRI requirement expected (company claim) | Serial MRI for ARIA | Varies |
Mechanism | Brain cortisol (11β-HSD1) | Amyloid clearance | Diverse |
Stage | Pivotal Phase 2b/3 readout Nov 2026 | Approved | Mostly Phase 2–3, many failures |
Combination potential | Yes (mechanism-independent) | — | Varies |



